EVGEN PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 GBX | 0.00% |
|
+3.23% | -50.00% |
| Apr. 26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
| Apr. 26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
Valuation
| Fiscal Period: Maart | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 25.18 | 5.965 | 28.23 | 12.65 | 12.54 | 4.258 |
| Enterprise Value (EV) 1 | 22.59 | 0.7792 | 11.87 | 1.317 | 6.315 | 2.072 |
| P/E ratio | -7.29 x | -1.71 x | -4 x | -3.7 x | -2.5 x | -0.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 103 x | - | 22.9 x | 8.76 x |
| EV / Revenue | - | - | 43.4 x | - | 11.5 x | 4.26 x |
| EV / EBITDA | -5.73 x | -0.2 x | -2.63 x | -0.33 x | -1 x | -0.42 x |
| EV / FCF | -6.52 x | -0.2 x | -2.88 x | -0.34 x | - | -0.53 x |
| FCF Yield | -15.3% | -495% | -34.7% | -297% | - | -188% |
| Price to Book | 9.52 x | 1.13 x | 1.69 x | 1.09 x | 1.89 x | 1.17 x |
| Nbr of stocks (in thousands) | 98,991 | 132,646 | 274,888 | 274,888 | 274,888 | 427,347 |
| Reference price 2 | 0.2543 | 0.0450 | 0.1027 | 0.0460 | 0.0456 | 0.009965 |
| Announcement Date | 6/13/19 | 6/15/20 | 6/15/21 | 6/8/22 | 6/7/23 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.2738 | - | 0.5487 | 0.486 |
| EBITDA 1 | -3.944 | -3.948 | -4.508 | -3.996 | -6.32 | -4.978 |
| EBIT 1 | -3.971 | -3.974 | -4.534 | -4.016 | -6.336 | -4.978 |
| Operating Margin | - | - | -1,656.2% | - | -1,154.76% | -1,024.28% |
| Earnings before Tax (EBT) 1 | -3.971 | -3.974 | -4.534 | -3.986 | -6.214 | -5.1 |
| Net income 1 | -3.34 | -3.408 | -3.773 | -3.433 | -5.019 | -4.371 |
| Net margin | - | - | -1,378.36% | - | -914.71% | -899.38% |
| EPS 2 | -0.0349 | -0.0264 | -0.0257 | -0.0124 | -0.0182 | -0.0158 |
| Free Cash Flow 1 | -3.466 | -3.859 | -4.122 | -3.915 | - | -3.886 |
| FCF margin | - | - | -1,505.68% | - | - | -799.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/13/19 | 6/15/20 | 6/15/21 | 6/8/22 | 6/7/23 | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2.59 | 5.19 | 16.4 | 11.3 | 6.23 | 2.19 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -3.47 | -3.86 | -4.12 | -3.91 | - | -3.89 |
| ROE (net income / shareholders' equity) | -88.2% | -86.5% | -22.6% | -26% | -55.5% | -189% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.0300 | 0.0400 | 0.0600 | 0.0400 | 0.0200 | 0.0100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 6/13/19 | 6/15/20 | 6/15/21 | 6/8/22 | 6/7/23 | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 4.26M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- EVG Stock
- Financials Evgen Pharma plc
